Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clover Biopharmaceuticals
Pharma
Novo, Merck, Hengrui-Elevar—Fierce Pharma Asia
In two deals potentially worth $2 billion each, Novo gained a "triple G" candidate from United Labs as Merck bought a CV asset from Hengrui.
Angus Liu
Mar 28, 2025 9:28am
Clover rejects Gavi demand for $224M repayment on COVID deal
Mar 24, 2025 11:36am
Moderna, Takeda and Everest—Fierce Pharma Asia
Sep 23, 2022 9:25am
Astellas, Fujifilm, Lundbeck-Otsuka—Fierce Pharma Asia
Jul 1, 2022 9:40am
'The Top Line' podcast: COVID shot makeover, M&A and more
Jul 1, 2022 6:00am
AZ-Daiichi, Biogen-Samsung, Clover and more—Fierce Pharma Asia
Sep 24, 2021 8:45am
